Abstract
A spinal cord injury leads to disturbances of sensory and motor signals due to the damage to white matter and myelinated fiber tracts. Moreover, the damage to gray matter causes segmental loss of interneurons of dorsal horn and motoneurons and restricts the therapeutic options. Neuroprotective strategies have the potential to improve the neurological outcome of patients. To achieve this, concerns to anesthetics or analgesics as neuroprotective interventions have been accumulating to explore neuroprotection during perioperative period.
This review includes consideration of: 1) basic concepts of the pathophysiological mechanisms following spinal cord injury and 2) anesthetics and analgesics displaying neuroprotective potential. In particular, we review the application of isoflurane as an inhalational neuroprotectant and discuss evidence for the neuroprotection provided by barbiturates. In addition, 3) recent advances in stem cell biology, neural injury and repair, and progress toward the development of neuroprotective and regenerative interventions are the basis for increased optimism.
Keywords: Spinal cord ischemia/injury, anesthetics, analgesic, neuroprotection, isoflurane, barbiturates, hypothermia, preconditioning, cellbased therapy/ transplantation.
Current Pharmaceutical Design
Title:Spinal Cord Ischemia/Injury
Volume: 20 Issue: 36
Author(s): Ishikawa T., Suzuki H., Ishikawa K., Yasuda S., Matsui T., Yamamoto M., Kakeda T., Yamamoto S., Owada Y. and Yaksh T.L.
Affiliation:
Keywords: Spinal cord ischemia/injury, anesthetics, analgesic, neuroprotection, isoflurane, barbiturates, hypothermia, preconditioning, cellbased therapy/ transplantation.
Abstract: A spinal cord injury leads to disturbances of sensory and motor signals due to the damage to white matter and myelinated fiber tracts. Moreover, the damage to gray matter causes segmental loss of interneurons of dorsal horn and motoneurons and restricts the therapeutic options. Neuroprotective strategies have the potential to improve the neurological outcome of patients. To achieve this, concerns to anesthetics or analgesics as neuroprotective interventions have been accumulating to explore neuroprotection during perioperative period.
This review includes consideration of: 1) basic concepts of the pathophysiological mechanisms following spinal cord injury and 2) anesthetics and analgesics displaying neuroprotective potential. In particular, we review the application of isoflurane as an inhalational neuroprotectant and discuss evidence for the neuroprotection provided by barbiturates. In addition, 3) recent advances in stem cell biology, neural injury and repair, and progress toward the development of neuroprotective and regenerative interventions are the basis for increased optimism.
Export Options
About this article
Cite this article as:
T. Ishikawa, H. Suzuki, K. Ishikawa, S. Yasuda, T. Matsui, M. Yamamoto, T. Kakeda, S. Yamamoto, Y. Owada and T.L. Yaksh, Spinal Cord Ischemia/Injury, Current Pharmaceutical Design 2014; 20 (36) . https://dx.doi.org/10.2174/1381612820666140204113252
DOI https://dx.doi.org/10.2174/1381612820666140204113252 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure-Activity Relationships of Biphalin Analogs and their Biological Evaluation on Opioid Receptors
Mini-Reviews in Medicinal Chemistry Recovery of Locomotor Function with Combinatory Drug Treatments Designed to Synergistically Activate Specific Neuronal Networks
Current Medicinal Chemistry Chirality of Central Nervous System (CNS) Acting Drugs: A Formidable Therapeutic Hurdle Against CNS Diseases
Central Nervous System Agents in Medicinal Chemistry Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Complementary and Alternative Medical Therapies in Fibromyalgia
Current Pharmaceutical Design Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Recent Advances in Superparamagnetic Iron Oxide Nanoparticles for Cellular Imaging and Targeted Therapy Research
Current Pharmaceutical Design Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Involvement of the Blood-Brain Barrier in Metabolic Regulation
CNS & Neurological Disorders - Drug Targets Glutamatergic Neurotransmission As Molecular Target of New Anticonvulsants
Current Topics in Medicinal Chemistry Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry Opioids in Neuropathic Pain
Current Pharmaceutical Design Pharmacological Manipulation of Neural Progenitor Pathways In Situ: Possibilities for Neural Restoration in the Injured Adult Brain
Current Medicinal Chemistry - Central Nervous System Agents Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology Commentary-1 Research Highlights (Never Underestimate the Power of Adenosine in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design In Utero Gene Therapy: Prospect and Future
Current Pharmaceutical Design Functional Genomics: New Insights into the Function of Low Levels of Gene Expression in Stem Cells
Current Genomics